NRX Pharmaceuticals (NRXP) Cash from Operations Growth (3y) (2020 - 2026)
NRX Pharmaceuticals (NRXP) Cash from Operations Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | - |
| 10 | NRX Pharmaceuticals | 122.51 Mn | 115.81 Mn | 437,000.00 | 10.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.95% |
| Dec 31, 2025 | 23.66% |
| Sep 30, 2025 | 22.73% |
| Jun 30, 2025 | 35.18% |
| Mar 31, 2025 | 30.53% |
| Dec 31, 2024 | 42.92% |
| Sep 30, 2024 | 42.32% |
| Jun 30, 2024 | 39.19% |
| Mar 31, 2024 | -6.78% |
| Dec 31, 2023 | -98.73% |
| Sep 30, 2023 | -59.25% |
| Jun 30, 2023 | -128.84% |
| Mar 31, 2023 | -330.28% |
| Dec 31, 2022 | -216.62% |
| Sep 30, 2022 | -392.94% |
| Jun 30, 2022 | -334.23% |
| Mar 31, 2022 | -226.69% |
| Sep 30, 2021 | -210.25% |
| Jun 30, 2021 | -224.03% |
| Mar 31, 2021 | -147.94% |